BRAF(V600E)-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma

Ovarian serous borderline tumor (SBT) is a known precursor of low-grade serous carcinoma. While most SBTs are cured surgically, some progress to carcinoma and a risk predictor for malignant relapse is needed to ensure vigilant follow-up and additional treatment. Activating mutations in KRAS or BRAF...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Chui, M. Herman, Kjaer, Susanne K., Frederiksen, Kirsten, Hannibal, Charlotte G., Wang, Tian-Li, Vang, Russell, Shih, Ie-Ming
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2019
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6901340/
https://ncbi.nlm.nih.gov/pubmed/31839880
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27326
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia